Anti-p16INK4a / CDKN2A, clone rCDKN2A/13303

0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide. CDKN2A antibody recombinant mouse mAb targets Cyclin-dependent kinase inhibitor 2A, a critical cell cycle regulatory protein encoded by the CDKN2A gene. Cyclin-dependent kinase inhibitor 2A is best known as p16 INK4a and functions as a negative regulator of cyclin-dependent kinases CDK4 and CDK6, thereby controlling progression through the G1 phase of the cell cycle. CDKN2A is predominantly localized to the nucleus, where it enforces cell cycle arrest by preventing phosphorylation of the retinoblastoma protein.As a member of the INK4 family of cyclin-dependent kinase inhibitors, Cyclin-dependent kinase inhibitor 2A plays a central role in cellular senescence, stress responses, and proliferation control. CDKN2A antibody, also commonly referred to as p16 INK4a antibody in the literature, is widely used to study mechanisms of cell cycle regulation and checkpoint integrity. In addition to nuclear localization, p16 INK4a may also be detected in the cytoplasm under certain biological conditions, reflecting changes in regulatory state or cellular context.Expression of CDKN2A is tightly regulated and influenced by oncogenic signaling, aging, and epigenetic modifications. CDKN2A antibody is therefore useful for examining pathways associated with senescence, cell cycle arrest, and tumor suppressor activity. Loss, overexpression, or mislocalization of Cyclin-dependent kinase inhibitor 2A has been widely investigated in disease-related research settings, particularly in studies focused on dysregulated cell proliferation.In cancer biology, CDKN2A is one of the most frequently studied tumor suppressor genes. Altered p16 INK4a expression is associated with abnormal cell cycle control and is commonly evaluated in tumor classification and mechanistic cancer research. CDKN2A antibody is routinely applied in studies examining cell cycle dysregulation, oncogenic transformation, and therapeutic response pathways.This CDKN2A antibody, clone rCDKN2A/13303, is designed to recognize Cyclin-dependent kinase inhibitor 2A in research applications. Recombinant mouse mAb clone rCDKN2A/13303 supports detection of CDKN2A expression and localization and is suitable for studies focused on cell cycle regulation, tumor suppressor signaling, and CDK pathway biology.